A Comparison of Efficacy of Two Brands of Enoxaparin in COVID-19 Patients: A Pilot Study
Dhvani Dave, Jalpa Suthar, Jhanvi Patel
Asian Journal of Medicine and Health · pp. 135–140 · Published 8 Oct 2022
10.9734/ajmah/2022/v20i11752Abstract
Introduction: Enoxaparin is a complex and biologically derived low-molecular-weight Heparin which is approved for a variety of clinical indications associated with thromboembolic events such as Deep Vein Thrombosis and Venous Thromboembolism. During COVID-19 it was frequently used as prophylaxis in the treatment of thromboembolic events. Nowadays, many brands have come up in the market for the same. Objective: In Tricolour Hospital located in Vadodara, Gujarat, the ongoing brand of Enoxaparin 0.6 i.e., Clexane (Sanofi) falls short as well as in the pharmaceutical market. Hence, the management decided to procure another brand of Enoxaparin until Clexane is available to the vendors. Therefore, the present study was planned to study efficacy of two brands of Enoxaparin –one is Coguparine, (Venus Pharmaceuticals) and another LMWX- (Abbott) in COVID-19 patients in an isolation ward of hospital. The aim of present study was to compare the efficacy of two brands of Enoxaparin (Coguparine vs LMWX) for prophylactic treatment of thromboembolism observed in COVID-19 patients. Methodology: Patients were randomly divided into 2 groups- A and B. Patients in group A received Coguparine while patients in group B received LMWX. Statistical analysis was carried out using paired t-test. Results: The laboratory reports of patients in Group-A presented few abnormal improvements in the Complete blood count but there was no concrete evidence about the same. On the other hand, patients in Group-B receiving LMWX showed improvement in CBC profile. Also, there was significant difference observed in C-Reactive Protein and D-Dimer profiles in both the brands. Conclusion: This showed that for the cost-effective treatment and procurement of Enoxaparin there is no harm in using generic formulation of Enoxaparin as and when required. But LMWX was proved to be of standard quality in terms of efficacy.
References (12)
- 1 Hematological findings and complications of COVID ‐19 [DOI]
- 2 C-reactive protein levels in the early stage of COVID-19 [DOI]
- 3 Mechanism of thrombocytopenia in COVID-19 patients [DOI]
- 4 COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation [DOI]
- 5 Prevalence of co‐morbidities and their association with mortality in patients with COVID ‐19: A systematic review and meta‐analysis [DOI]
- 6 Eosinophil responses during COVID-19 infections and coronavirus vaccination [DOI]
- 7 Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis [DOI]
- 8 Elevated d-Dimer Levels Are Associated With Increased Risk of Mortality in Coronavirus Disease 2019 [DOI]
- 9 Coronavirus Disease 2019 (COVID–19): A Short Review on Hematological Manifestations [DOI]
- 10 Thromboembolic disease in COVID-19 patients: A brief narrative review [DOI]
- 11 Generic versus branded enoxaparin in prophylaxis and treatment of vein thrombosis [DOI]
- 12 Comparative Studies on Branded Enoxaparin and a US Generic Version of Enoxaparin [DOI]
Cited by 0
No indexed citations yet.
Related research
- A Randomized Placebo Controlled Study to Determine the Efficacy of Oral Diclofenac Sodium in the Treatment of Symptomatic Osteoarthritis of the Knee in Nnewi, South Eastern Nigeria — shares topic coverage
- Bacteriological and Fungal Evaluation of Three Brands of Disinfectants Sold in Calabar Municipality, Cross River State — shares topic coverage
- Drug Interactions, Safety and Efficacy of Probiotics — shares topic coverage
- The Efficacy of the Volume of Hyperbaric Bupivacaine Used and Its Influence on Spinal Anaesthesia Induced Hypotension during Caesarean Section — shares topic coverage
- The Efficacy of Saline Nasal Irrigation in Chronic Rhinosinusitis: A Single Centre Experience — shares topic coverage
Article metrics
Real usage data collected on this platform.
6
Page views
0
PDF downloads
0
Outbound clicks
0
Citations
Views over time
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
Traffic sources
Referring site, by host.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.